The vascular disrupting agents market

London

 

Roots Analysis has announced the addition of “Vascular Disrupting Agents Market, 2021-2030” report to its list of offerings.

 

Despite multiple cancer treatment options, there is an evident unmet need for anti-cancer therapies with better efficacy and less toxicity. The vascular disrupting agents, which target the established tumor vasculature and disrupt blood flow to cancerous tissue, have garnered considerable interest as a novel anticancer therapeutic modality. 

 

To order this 290+ page report, which features 110+ figures and 125+ tables, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html

 

Key Market Insights

 

Currently, more than 120 vascular disrupting agents are in the development pipeline

Around 50% of the vascular disrupting agents are being evaluated in phase II clinical trials, while more than 5% are either marketed or in phase III of development. Examples of phase III drugs include Bavituximab (non-small cell lung cancer), Icaritin (hepatocellular carcinoma), NGR-TNF (malignant pleural mesothelioma), Padeliporfin (transitional cell cancer of renal pelvis and ureter), Plinabulin (non-small cell lung cancer, chemotherapy-induced neutropenia) and VB-111 (glioblastoma, recurrent platinum resistant ovarian cancer). Further, 35% molecules are in phase I trials.

 

Around 30 industry and non-industry players are engaged in the development of vascular disrupting agents

Around 40% of these firms are start-ups / small players (with less than 50 employees). It is also worth highlighting that, majority of the firms engaged in this domain (56%) are based in North America, followed by Asia Pacific (25%) and Europe (19%).

 

Over 265 eminent scientists (identified as key opinion leaders (KOLs)) are involved in the clinical trials of vascular disrupting agents

Around 50% of these KOLs are associated with the organizations based in North America, followed by those in Asia Pacific (38%) and Europe (12%). Majority of these KOLs are currently affiliated to hospitals and medical centers.

 

The market is anticipated to grow at a CAGR of over 60%, during the period 2021-2030

Growth in this domain is anticipated to be driven by the drugs that are being developed for the treatment of non-small cell lung cancer. North America (primarily the US) and Europe are expected to capture around 50% of the market share by 2030, in terms of the sales-based revenues.

 

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market/request-sample.html             

For additional details, please visit 

https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html

or email sales@rootsanalysis.com

 

 

You may also be interested in the following titles:

  1. TIL-based Therapies Market, 2021-2030
  2. TCR-based Therapies Market, 2021-2030
  3. Peptide Therapeutics Market, 2021-2030

 

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *